ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
October 04, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and...
Selux Diagnostics Receives $8.0 Million in Additional Funding to Redefine Speed in Microbiology Laboratory Testing
July 12, 2022 10:30 ET
|
Selux Diagnostics, Inc.
BOSTON, July 12, 2022 (GLOBE NEWSWIRE) -- Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antimicrobial resistance (AMR), today...
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
June 14, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
April 06, 2022 12:14 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that a team of three company scientists were named one of the winners of the Pediatric...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
January 24, 2022 15:52 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
RIVANNA® Expands World-Class Engineering Team to Advance Development of the Accuro® Product Platform
January 18, 2022 06:00 ET
|
Rivanna Medical
CHARLOTTESVILLE, Va., Jan. 18, 2022 (GLOBE NEWSWIRE) -- RIVANNA®, developers of world-first, imaging-based medical solutions, today announced the appointment of Paul Sheeran, Ph.D., as senior...
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
November 17, 2021 06:42 ET
|
Vir Biotechnology, Inc.
– US government contracts for approximately $1 billion1 (USD) now in place to purchase sotrovimab, further expanding access nationwide – – This brings the total number of doses secured through...
RIVANNA Purchases New Facility Signaling Rapid Growth
November 09, 2021 06:00 ET
|
Rivanna Medical
CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RIVANNA®, developers of world-first, imaging-based medical solutions, today announced the purchase of a 10,000 square-foot facility in...
RIVANNA announces award from U.S. government to develop Accuro Platform for rapid triage of blast-related injuries
October 26, 2021 09:00 ET
|
RIVANNA
CHARLOTTESVILLE, Va., Oct. 26, 2021 (GLOBE NEWSWIRE) -- RIVANNA®, developers of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research...